Medical Insights with Dr. Thomas Blom

In this episode of Medical Insights with Dr. Thomas Blom, Dr. Blom sits down with medical oncologist Dr. Richard Lee to discuss the rapidly evolving landscape of breast cancer treatment.Together, they break down three major advances transforming modern oncology: optimizing Ovarian Function Suppression (OFS) in early-stage premenopausal patients, leveraging circulating tumor DNA (ctDNA) and Breast Cancer Index (BCI) for precision risk stratification, and navigating the rise of Antibody-Drug Conjugates (ADCs) like Enhertu across frontline settings.Key Episode TopicsOvarian Function Suppression (OFS): How shutting down ovarian function in premenopausal, ER-positive patients mimics chemotherapy-induced menopause to prevent recurrence in high-risk early-stage breast cancer.De-escalation & Risk Stratification: Utilizing genomic tools like Oncotype DX and the Breast Cancer Index (BCI) to tailor extended endocrine therapy (years 5–10) and safely reduce cytotoxic chemotherapy reliance.Endocrine Resistance & Novel Oral SERDs: Managing ESR1 mutation escape mechanisms with next-generation oral selective estrogen receptor degraders (SERDs) like elacestrant, imlunestrant, and camizestrant.Liquid Biopsy & ctDNA Monitoring: How blood-based circulating tumor DNA testing allows clinicians to detect emerging mutations and genomic progression before radiographic changes occur.Antibody-Drug Conjugates (ADCs): The "guided missile" approach to targeted chemotherapy delivery—exploring how drugs like Enhertu (trastuzumab deruxtecan) are shifting into HER2-low, HER2-ultralow, and pre-surgical neoadjuvant settings.References & Mentioned StudiesSOFT & TEXT Trials: Landmark clinical trials validating the survival benefit of adding ovarian function suppression to tamoxifen or aromatase inhibitors in premenopausal women.RXPONDER Trial: Evaluating genomic recurrence scoring and chemotherapy benefits in node-positive, HR-positive breast cancer.SERENA-6 Trial: Investigating ctDNA-guided treatment switches to oral SERDs upon detection of emergent ESR1 mutations prior to radiographic progression.ATLAS & MA17R Trials: Clinical data supporting extended duration endocrine therapy beyond the initial 5 years.About The ShowMedical Insights with Dr. Thomas Blom brings you in-depth discussions with leading medical experts on the latest innovations, clinical trial data, and treatment strategies reshaping modern healthcare and patient outcomes.Disclaimer: Medical Insights with Dr. Thomas Blom is for educational and entertainment purposes only and does not substitute for professional medical advice, diagnosis, or treatment.

In this episode of Medical Insights, Dr. Thomas Blom sits down with Dr. Andrew Evens of Rutgers Cancer Institute about major advances in Hodgkin lymphoma. They review the disease’s treatment history from early radiation to MOPP and long-standing ABVD, then focus on recent efforts to maintain high cure rates while reducing long-term toxicity. Evens describes the Holistic (Hodgkin International Study for Individualized Care) consortium, which uses clinical trial and registry data from 30 centers and 30,000+ cases to provide dynamic, individualized risk estimates and future projections of late effects. For advanced-stage disease, they discuss the shift from brentuximab-based therapy after ECHELON-1 to nivolumab-AVD after SWOG 1826, citing improved efficacy and tolerability. They cover European BreCAV use, early-stage ABVD decision factors, limited post-treatment imaging, and a planned relapse trial (TARGET-HL) testing transplant-sparing targeted therapy plus radiation.00:00 Welcome and Overview00:42 Hodgkin Treatment History03:10 Holistic Risk Model11:46 Advanced Stage Standards17:21 Europe vs North America22:41 Early Stage Strategy30:36 Survivorship Monitoring35:03 Relapse and New Trials39:03 Closing Thoughts

In this special episode of Medical Insights with Dr. Thomas Blom, we step away from our usual oncology FAQ to debut our very first Historical Morbidity and Mortality case. Joining Dr. Blom is his longtime friend and the show's first-ever pulmonary and critical care specialist, Dr. Harshit Rao from Dallas, Texas.Together, they transport a legendary American founding father into the modern ICU. On October 8, 1793, 56-year-old Massachusetts Governor John Hancock passed away suddenly after a rapid, 60-minute acute respiratory and neurological decline. Using historical records, Dr. Blom and Dr. Rao reconstruct Hancock’s final days, dissect his severe medical history—including decades of debilitating tophaceous gout and suspected malignant hypertension—and build a modern differential diagnosis for what truly killed the man behind the famous signature. What You’ll Learn In This Episode:The Case Profile: A deep dive into John Hancock's lifestyle, affluent high-purine diet, significant alcohol consumption, and extreme occupational stress managing the American Revolution.The History of Podagra: How Hancock suffered from severe, crippling tophaceous gout that left him largely bedridden and cachectic toward the end of his life.The Final Hour: A chronological breakdown of October 8, 1793, from his sudden 7:00 AM onset of dyspnea (shortness of breath) and stupor to his death at 8:00 AM.The Modern ICU Workup: How modern Emergency Medical Services (EMS) and critical care physicians would treat and diagnose a patient presenting in this state today (from rapid intubation to CT angiograms).Historical Medical Trivia: The surprising connection between Benjamin Franklin, a French physician, and the introduction of the autumn crocus (Colchicum autumnale)—the precursor to modern colchicine—to the United States. The Modern Differential DiagnosisWithout modern laboratory testing or imaging, Dr. Blom and Dr. Rao weigh the most likely culprits behind Hancock's rapid demise:Pulmonary Embolism (PE): Highly probable given his prolonged immobility and chronic bedbound state.Cardiovascular Event: Acute Myocardial Infarction (AMI) or a malignant arrhythmia stemming from chronic kidney disease.Sepsis / Septic Arthritis: An infection potentially infiltrating his severely damaged, tophaceous joints.Colchicine Toxicity: Could his primitive homeopathic remedies have built up to toxic levels due to progressive renal failure?Pneumonia: A common terminal event for chronically ill, bedbound patients in the 18th century. About Our GuestDr. Harshit Rao is a Pulmonary and Critical Care Specialist based in Dallas, Texas. He completed his residency training alongside Dr. Thomas Blom and brings over 20 years of intensive care experience to the podcast.Disclaimer: Medical Insights with Dr. Thomas Blom is for educational and entertainment purposes only and does not substitute for professional medical advice, diagnosis, or treatment.#JohnHancock #MedicalHistory #Podcast #Gout #CriticalCare #Medicine #History #FoundingFathers

The treatment landscape for multiple myeloma is shifting at absolute lightning speed. In this episode, we dive deep into the latest clinical breakthroughs, emerging frontline standards, and the groundbreaking immunotherapies rapidly redefining patient care.Joining the conversation is Dr. Dan Vogl, Associate Professor of Medicine and Myeloma Specialist at Penn Medicine's Abramson Cancer Center. Together, we break down the complex balancing act between treatment efficacy, long-term toxicity, and modern sequencing strategy. We examine everything from the transition toward quadruplet induction therapy to the revolutionary potential of off-the-shelf T-cell engagers and personalized cellular therapies.KEY TAKEAWAYS FROM THIS EPISODE:The Evolution of Frontline Therapy: Moving from triplet regimens to quadruplet combinations, and how the addition of monoclonal antibodies like daratumumab is shaping expectations for newly diagnosed patients.The Overall Survival Confounding Dilemma: Why evaluating long-term survival metrics in clinical trials has become increasingly difficult, and why clinical endpoints like progression-free survival (PFS) remain a point of healthy debate among oncologists.Redefining Transplant Eligibility: Shifting the conversation away from binary age limits and toward a more comprehensive, nuanced assessment of patient frailty and functional resilience.The Rise of Bispecific Antibodies (TCEs): A clear look at how dual-targeting therapies work to engage the immune system, their expanding role in early relapse, and insights into Penn's ongoing trials testing fixed-duration vs. indefinite dosing.CAR T-Cell Therapy in Practice: Demystifying the logistical timeline, cellular manufacturing process, and profound clinical response rates of chimeric antigen receptor T-cell therapies, alongside a candid look at rare, long-term toxicities.The Future of Community-Based Oncology: How specialized care delivery models are scaling to bring advanced, high-stakes immunotherapies safely to regional hospitals and community cancer centers.If you find this deep dive into modern hematologic oncology helpful, please hit that subscribe button, leave a comment with your thoughts, and share the episode with colleagues or families navigating a multiple myeloma journey.Disclaimer: The information provided in this podcast is for educational and informational purposes only and should not be construed as medical advice. Always consult with a qualified healthcare professional regarding any medical condition or treatment plan.#MultipleMyeloma #OncologyPodcast #CancerResearch

This episode of Medical Insights with Dr. Thomas Blom features Dr. John Heim, a thoracic surgeon from Penn Medicine Princeton. The discussion focuses on the common clinical scenario of discovering pulmonary nodules through imaging and the strategic approach to managing early-stage lung cancer.Episode OverviewIn an era of increased CT imaging, "incidental" pulmonary nodules are being found more frequently than ever. Dr. Blom and Dr. Heim break down the anxiety surrounding these findings, the actual statistical risks of cancer, and the protocols used to ensure patient safety while avoiding unnecessary surgery.Key Discussion PointsDefining the Nodule: Why a "growth" or "tumor" doesn't always mean cancer.The 15% Rule: Statistically, 15 out of 100 people over age 50 have lung nodules, but only a small fraction are malignant.Fleischner Society Guidelines: The history and importance of these protocols in determining when to watch a nodule and when to intervene.Risk Factors Beyond Smoking: The roles of radon and asbestos exposure in lung cancer development.Advanced Imaging (PET Scans): How sugar metabolism helps identify hypermetabolic activity in potential tumors.The Biopsy Process: Understanding bronchoscopy, EBUS (Endoscopic Bronchial Ultrasound), and CT-guided biopsies.Surgical Philosophy: Why staging and pathology are the most critical steps before entering the operating room.Subscribe for more medical insights and deep dives into modern healthcare management.#LungCancer #Oncology